Shanghai Junshi Biosciences Co., Ltd. (SHJBF)
USD 1.97
(51.54%)
USD 1.97
(51.54%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 11.36 Billion CNY | -9.52% |
| 2022 | 12.55 Billion CNY | 13.64% |
| 2021 | 11.05 Billion CNY | 37.95% |
| 2020 | 8.01 Billion CNY | 81.14% |
| 2019 | 4.42 Billion CNY | 3.88% |
| 2018 | 4.25 Billion CNY | 249.04% |
| 2017 | 1.21 Billion CNY | 6.15% |
| 2016 | 1.14 Billion CNY | 82.86% |
| 2015 | 628.38 Million CNY | 88.74% |
| 2014 | 332.93 Million CNY | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q3 | 1.54 Billion USD | -1.55% |
| 2024 Q2 | 11 Billion CNY | -8.47% |
| 2024 Q1 | 1.66 Billion USD | 6.18% |
| 2023 Q4 | 1.59 Billion USD | 0.81% |
| 2023 FY | 11.36 Billion CNY | -9.52% |
| 2023 Q1 | 1.76 Billion USD | -85.95% |
| 2023 Q2 | 11.79 Billion CNY | 568.55% |
| 2023 Q3 | 1.58 Billion USD | -86.56% |
| 2022 Q1 | 10.95 Billion USD | -0.88% |
| 2022 Q3 | 1.35 Billion USD | -86.36% |
| 2022 Q4 | 12.55 Billion CNY | 829.78% |
| 2022 FY | 12.55 Billion CNY | 13.64% |
| 2022 Q2 | 9.9 Billion CNY | -9.59% |
| 2021 Q2 | 10.04 Billion CNY | 17.42% |
| 2021 FY | 11.05 Billion CNY | 37.95% |
| 2021 Q4 | 11.05 Billion CNY | 15.21% |
| 2021 Q3 | 9.59 Billion USD | -4.49% |
| 2021 Q1 | 8.55 Billion USD | 6.76% |
| 2020 Q4 | 8.01 Billion CNY | -1.51% |
| 2020 FY | 8.01 Billion CNY | 81.14% |
| 2020 Q3 | 8.13 Billion CNY | 78.13% |
| 2020 Q2 | 4.56 Billion CNY | 0.0% |
| 2020 Q1 | - CNY | -100.0% |
| 2019 Q4 | 4.42 Billion CNY | 0.0% |
| 2019 Q1 | 4.45 Billion CNY | 4.67% |
| 2019 FY | 4.42 Billion CNY | 3.88% |
| 2019 Q2 | 4.64 Billion CNY | 4.15% |
| 2018 Q2 | 1.53 Billion CNY | 0.0% |
| 2018 Q1 | - CNY | -100.0% |
| 2018 FY | 4.25 Billion CNY | 249.04% |
| 2018 Q4 | 4.25 Billion CNY | 186.93% |
| 2018 Q3 | 1.48 Billion CNY | -3.53% |
| 2017 Q2 | 1.32 Billion CNY | 0.0% |
| 2017 Q4 | 1.21 Billion CNY | 0.0% |
| 2017 FY | 1.21 Billion CNY | 6.15% |
| 2017 Q1 | 1.32 Billion CNY | 15.56% |
| 2016 FY | 1.14 Billion CNY | 82.86% |
| 2016 Q2 | 860.32 Million CNY | 0.0% |
| 2016 Q1 | 860.32 Million CNY | 36.91% |
| 2016 Q4 | 1.14 Billion CNY | 0.0% |
| 2016 Q3 | 1.14 Billion CNY | 33.56% |
| 2015 Q1 | 137.03 Million CNY | -58.84% |
| 2015 FY | 628.38 Million CNY | 88.74% |
| 2015 Q3 | 628.38 Million CNY | 358.54% |
| 2015 Q4 | 628.38 Million CNY | 0.0% |
| 2015 Q2 | 137.03 Million CNY | 0.0% |
| 2014 Q4 | 332.93 Million CNY | 0.0% |
| 2014 FY | 332.93 Million CNY | 0.0% |
| 2014 Q3 | 332.93 Million CNY | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| Qrons Inc. | 420.00 USD | -2705348471.429% |
| Santhera Pharmaceuticals Holding AG | 130.21 Million USD | -8626.211% |
| Nascent Biotech, Inc. | 552.12 Thousand USD | -2057870.007% |
| Adynxx, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 687.48 Thousand USD | -1652655.692% |
| Capstone Therapeutics Corp. | 52.7 Million USD | -21460.244% |
| BioStem Technologies, Inc. | 14.56 Million USD | -77937.341% |
| CSL Limited | 38.02 Billion USD | 70.116% |
| Arch Therapeutics, Inc. | 1.95 Million USD | -580153.694% |
| Evofem Biosciences, Inc. | 10.55 Million USD | -107560.262% |
| Northwest Biotherapeutics, Inc. | 27.94 Million USD | -40561.552% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -3213112.034% |
| Skye Bioscience, Inc. | 11.94 Million USD | -95059.739% |
| ProtoKinetix, Incorporated | 480.55 Thousand USD | -2364336.269% |
| Rebus Holdings, Inc. | 5000.00 USD | -227249180.0% |
| Burzynski Research Institute, Inc. | 2310.00 USD | -491881458.442% |
| Neon Bloom, Inc. | 770.64 Thousand USD | -1474311.531% |
| Eiger BioPharmaceuticals, Inc. | 38.84 Million USD | -29149.27% |
| Nanobac Pharmaceuticals, Incorporated | 7.21 Million USD | -157280.036% |
| Institute of Biomedical Research Corp. | 76.35 Thousand USD | -14881195.021% |
| SQZ Biotechnologies Company | 107.18 Million USD | -10500.599% |
| Intellipharmaceutics International Inc. | 1.43 Million USD | -793350.426% |
| Propanc Biopharma, Inc. | 72.36 Thousand USD | -15701501.603% |
| Mesoblast Limited | 667.9 Million USD | -1601.221% |
| Marizyme, Inc. | 22.01 Million USD | -51512.198% |
| Genus plc | 1.02 Billion USD | -1004.331% |
| VioQuest Pharmaceuticals, Inc. | 1.35 Million USD | -836388.306% |
| Pharming Group N.V. | 462.85 Million USD | -2354.87% |
| Therapeutic Solutions International, Inc. | 3.31 Million USD | -342864.77% |
| CNBX Pharmaceuticals Inc. | 499.03 Thousand USD | -2276768.942% |
| Nymox Pharmaceutical Corporation | 627 Thousand USD | -1812095.215% |
| ContraFect Corporation | 20.67 Million USD | -54846.874% |
| PsyBio Therapeutics Corp. | 390.36 Thousand USD | -2910620.708% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 382.17 Thousand USD | -2972989.432% |
| IMV Inc. | 31.33 Million USD | -36162.658% |
| AXIM Biotechnologies, Inc. | 4.14 Million USD | -273957.012% |
| MultiCell Technologies, Inc. | 126.22 USD | -9002110500.539% |
| ONE Bio Corp. | 70.08 Million USD | -16112.288% |
| Accustem Sciences Inc. | 939.68 Thousand USD | -1209072.822% |
| RVL Pharmaceuticals plc | 128.51 Million USD | -8741.696% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 431.71 Thousand USD | -2631842.443% |
| Q BioMed Inc. | 3.51 Million USD | -323108.905% |
| Emmaus Life Sciences, Inc. | 35.17 Million USD | -32198.997% |
| Mosaic ImmunoEngineering Inc. | 261.27 Thousand USD | -4348719.069% |
| Biomind Labs Inc. | 73.81 Thousand USD | -15392229.888% |
| American Oriental Bioengineering, Inc. | 446.3 Million USD | -2445.874% |
| Provectus Biopharmaceuticals, Inc. | 1.44 Million USD | -784143.98% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 30.01 Million USD | -37756.013% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | 2.74 Million USD | -413631.901% |
| Curative Biotechnology, Inc. | 2.6 Million USD | -436381.31% |
| GB Sciences, Inc. | 103.44 Thousand USD | -10984281.586% |
| Alpha Cognition Inc. | 2.45 Million USD | -463263.633% |
| HST Global, Inc. | 1526.00 USD | -744591249.934% |
| Wesana Health Holdings Inc. | 987.96 Thousand USD | -1149985.377% |
| Halberd Corporation | 10.13 Thousand USD | -112155304.205% |
| Enzolytics Inc. | 361.7 Million USD | -3041.348% |
| Agentix Corp. | 261.39 Thousand USD | -4346805.797% |
| Resverlogix Corp. | 8.11 Million USD | -139918.041% |
| Nuo Therapeutics, Inc. | 1.87 Million USD | -604968.694% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 4.54 Billion USD | -150.139% |
| Enzon Pharmaceuticals, Inc. | 47.7 Million USD | -23719.681% |
| Endonovo Therapeutics, Inc. | 639.65 Thousand USD | -1776239.783% |
| RespireRx Pharmaceuticals Inc. | 22.78 Thousand USD | -49876832.531% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 8.94 Million USD | -126866.892% |
| AVAX Technologies, Inc. | 7.37 Million USD | -153922.261% |
| Zenith Capital Corp. | 7410.00 USD | -153339495.142% |
| Genscript Biotech Corporation | 3.38 Billion USD | -235.534% |
| Ember Therapeutics, Inc. | 184.00 USD | -6175252073.913% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 321.8 Thousand USD | -3530742.806% |
| WPD Pharmaceuticals Inc. | 261.36 Thousand USD | -4347271.482% |
| Cotinga Pharmaceuticals Inc. | 927.96 Thousand USD | -1224354.907% |
| Kadimastem Ltd | 2.3 Million USD | -493045.377% |
| Helix BioMedix, Inc. | 3.02 Million USD | -375507.966% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 57.09 Thousand USD | -19901227.635% |
| LadRx Corporation | 2.3 Million USD | -492232.97% |
| Cell Source, Inc. | 195.17 Thousand USD | -5821699.345% |
| Regen BioPharma, Inc. | 353.61 Thousand USD | -3213112.034% |
| NovAccess Global Inc. | 62.24 Thousand USD | -18253440.676% |
| Affymax, Inc. | 7.44 Million USD | -152559.734% |
| Itoco Inc. | 1.4 Million USD | -811462.834% |
| Rasna Therapeutics, Inc. | 95.65 Thousand USD | -11878240.32% |
| Pathfinder Cell Therapy, Inc. | 106 Thousand USD | -10719205.66% |
| Mobile Lads Corp. | 52.00 USD | -21850892207.692% |
| CytoDyn Inc. | 11.13 Million USD | -101933.621% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 142.97 Thousand USD | -7947235.143% |
| NanoSphere Health Sciences Inc. | 17.88 Thousand USD | -63548356.376% |
| Alseres Pharmaceuticals, Inc. | 385.47 Thousand USD | -2947583.224% |
| SYBLEU INC | 330.46 Thousand USD | -3438194.782% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 409.42 Thousand USD | -2775145.102% |
| International Stem Cell Corporation | 5.39 Million USD | -210706.382% |
| Bioxytran, Inc. | 137.63 Thousand USD | -8255224.838% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 15 Million USD | -75640.52% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 16.57 Million USD | -68435.28% |
| Adhera Therapeutics, Inc. | 79 Thousand USD | -14382765.823% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 864.67 Thousand USD | -1313970.341% |
| Innovation Pharmaceuticals Inc. | 7.51 Million USD | -151056.898% |
| Neutra Corp. | 2851.00 USD | -398543007.682% |
| Windtree Therapeutics, Inc. | 32.4 Million USD | -34962.84% |
| PureTech Health plc | 693.97 Million USD | -1537.306% |
| Coeptis Therapeutics, Inc. | 8.07 Million USD | -140679.813% |
| IXICO plc | 15.84 Million USD | -71615.057% |
| IntelGenx Technologies Corp. | 8.28 Million USD | -137094.687% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -10896.926% |
| CSL Limited | 38.02 Billion USD | 70.116% |
| Cellectis S.A. | 333.99 Million USD | -3301.99% |